Warning letter
Hill Dermaceuticals, Inc. [ARCHIVED]: warning letter of Aug 18, 2009
FDA warning letter 69923 · Center for Drug Evaluation and Research
Key facts
| Reference number | 69923 |
|---|---|
| Company | Hill Dermaceuticals, Inc. [ARCHIVED] |
| Subject | Prescription Drug Products/Labeling/Misbranded |
| Issue date | Aug 18, 2009 |
| Posted date | Aug 18, 2009 |
| Issuing office | Center for Drug Evaluation and Research |
| Product type | Drugs |
| CFR sections cited | 201.5, 201.100(c)(2), 314.70 |
| Inspection city | Sanford |
| Inspection ZIP | 32773-9311 |
| Inspection start date | Sep 15, 2008 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: